Use of GBT013, a Collagen-Based Dressing, for the Healing of Diabetic Foot Ulcers A Case Series

被引：0

作者：

Dumont, Isabelle J. ^{[1
]}

Lepeut, Marc ^{[2
]}

Segalen, Coralie ^{[3
]}

Guillemin, Yannis ^{[3
]}

Gouze, Jean Noel ^{[3
]}

机构：

[1] Foot Ctr Ransart, Brussels, Belgium

[2] Ctr Hosp Roubaix, Roubaix, France

[3] Genbiotech, 280 Rue Goa, F-06600 Antibes, France

来源：

JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION | 2018年 / 108卷 / 05期

关键词：

STANDARD TREATMENT; EFFICACY; MANAGEMENT; SAFETY; MATRIX-METALLOPROTEINASE-9; BECAPLERMIN; DURATION; COSTS; TRIAL; RISK;

D O I：

暂无

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

The number of people with diabetes is expected to reach 592 million in the year 2035. Diabetic foot lesions are responsible for more hospitalizations than any other complication of diabetes. The aims of this study were to examine for the first time a new biocompatible and biodegradable tridimensional collagen-based matrix, GBT013, in humans for diabetic foot ulcer wound healing and to evaluate its ease of use to better define a protocol for a future clinical trial. Seven adult patients with a diabetic foot ulcer of grade 1 A to 3D (University of Texas Diabetic Wound Classification) were treated using GBT013, a new collagen-based advance dressing and were monitored in two specialized foot care units for a maximum of 9 weeks. Five of seven wounds achieved complete healing in 4 to 7 weeks. Nonhealed ulcers showed a significant reduction of the wound surface (>44%). GBT013 was well tolerated and displayed positive wound healing outcomes as a new treatment strategy of chronic foot ulcers in diabetic patients.

引用

页码：419 / 429

页数：11

共 24 条

[1] Validation of a diabetic wound classification system - The contribution of depth, infection, and ischemia to risk of amputation
Armstrong, DG
Lavery, LA
Harkless, LB
[J]. DIABETES CARE, 1998, 21 (05) : 855 - 859
[2] A clinical trial of Integra Template for diabetic foot ulcer treatment
Driver, Vickie R.
Lavery, Lawrence A.
Reyzelman, Alexander M.
Dutra, Timothy G.
Dove, Cyaandi R.
Kotsis, Sandra V.
Kim, Hyungjin Myra
Chung, Kevin C.
[J]. WOUND REPAIR AND REGENERATION, 2015, 23 (06) : 891 - 900
[3] The Costs of Diabetic Foot The Economic Case for the Limb Salvage Team
Driver, Vickie R.
Fabbi, Matteo
Lavery, Lawrence A.
Gibbons, Gary
[J]. JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, 2010, 100 (05) : 335 - 341
[4] A proof-of-concept study of the effectiveness of a removable device for offloading in patients with neuropathic ulceration of the foot: the Ransart boot
Dumont, I. J.
Lepeut, M. S.
Tsirtsikolou, D. M.
Popielarz, S. M.
Cordonnier, M. M.
Fayard, A. J.
Devemy, F.
Fernandez, E.
Basuyaux, O.
Jeffcoate, W. J.
[J]. DIABETIC MEDICINE, 2009, 26 (08) : 778 - 782
[5] Apligraf in the Treatment of Neuropathic Diabetic Foot Ulcers
Edmonds, Michael
[J]. INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS, 2009, 8 (01) : 11 - 18
[6] Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L.
Whiting, D. R.
Hambleton, I.
Beagley, J.
Linnenkamp, U.
Shaw, J. E.
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 (02) : 137 - 149
[7] Efficacy of a collagen-based dressing in an animal model of delayed wound healing
Guillemin, Y.
Le Broc, D.
Segalen, C.
Kurkdjian, E.
Gouze, J. N.
[J]. JOURNAL OF WOUND CARE, 2016, 25 (07) : 406 - 413
[8] Landry GJ, 2011, ARCH SURG-CHICAGO, V146, P1005, DOI 10.1001/archsurg.2011.206
[9] Risk factors for foot infections in individuals with diabetes
Lavery, Lawrence A.
Armstrong, David G.
Wunderlich, Robert P.
Mohler, M. Jane
Wendel, Christopher S.
Lipsky, Benjamin A.
[J]. DIABETES CARE, 2006, 29 (06) : 1288 - 1293
[10] Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers
Li, Zhihong
Guo, Shuqin
Yao, Fang
Zhang, Yunliang
Li, Tingting
[J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2013, 27 (04) : 380 - 382

← 1 2 3 →